How about Zhejiang Shangyao Xinxin Pharmaceutical Co., Ltd.?

Zhejiang Shangyao Xinxin Pharmaceutical Co., Ltd. is a limited liability company (invested or controlled by a natural person) registered in Shangcheng District, Hangzhou, Zhejiang Province on 0/0/-0/2, 2005. The registered address is located at the 8th floor, No.4 Wangjiang International Center, Shangcheng District, Hangzhou, Zhejiang Province.

The unified social credit code/registration number of Zhejiang Shangyao Xinxin Pharmaceutical Co., Ltd. is 913301027 708034671,and Liu Yanling is an enterprise legal person. At present, the enterprise is in the state of opening.

The business scope of Zhejiang Shangyao Xinxin Pharmaceutical Co., Ltd. is: wholesale: Chinese herbal pieces, proprietary Chinese medicines, chemical pharmaceutical preparations, chemical raw materials, antibiotic raw materials, biochemical drugs, biological products, toxic drugs for medical use, protein assimilation preparations, peptide hormones, psychotropic drugs (limited to the second category) and medical devices; Sales: prepackaged foods, health food, formula food for special medical use, infant formula milk powder, other infant formula foods, laboratory equipment, experimental consumables and experimental reagents (except dangerous chemicals and precursor chemicals); Services: new drug research and development, medical information consultation, exhibitions and conferences. (Projects subject to approval according to law can only be operated after approval by relevant departments). In Zhejiang Province, the total registered capital of companies with similar business scope is 2215.67 million yuan, and the main capital is concentrated in 87 enterprises with a scale of10000-50 million and over 50 million. In the province, the registered capital of enterprises is excellent.

Zhejiang Shangyao Xinxin Pharmaceutical Co., Ltd. invested in 3 foreign companies and 0 branches.

See more information and materials of Zhejiang Shangyao Xinxin Pharmaceutical Co., Ltd. through Baidu Enterprise Credit.